These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 22890083

  • 1. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 2. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, Tamaki S, Kato T, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Izumi N.
    Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.
    J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
    [Abstract] [Full Text] [Related]

  • 4. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K.
    J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 7. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
    Onkologie; 2011 Jan 01; 34(10):538-42. PubMed ID: 21985853
    [Abstract] [Full Text] [Related]

  • 8. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
    Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT.
    J Hepatol; 2011 Oct 01; 55(4):858-65. PubMed ID: 21338641
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL.
    Cancer; 2010 Oct 01; 116(19):4590-6. PubMed ID: 20572033
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY.
    Oncology; 2011 Oct 01; 80(3-4):167-74. PubMed ID: 21701230
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Oct 01; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 14. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM.
    J Gastroenterol Hepatol; 2011 Nov 01; 26(11):1612-8. PubMed ID: 21517968
    [Abstract] [Full Text] [Related]

  • 15. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han KH, Choi JY, Kim DY.
    J Vasc Interv Radiol; 2019 Aug 01; 30(8):1194-1200.e1. PubMed ID: 31235408
    [Abstract] [Full Text] [Related]

  • 16. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.
    Radiology; 2013 Aug 01; 268(2):431-9. PubMed ID: 23616632
    [Abstract] [Full Text] [Related]

  • 17. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, Oi I, Fujino MA.
    Oncology; 2016 Aug 01; 91(6):317-330. PubMed ID: 27784014
    [Abstract] [Full Text] [Related]

  • 18. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K.
    J Gastroenterol Hepatol; 2011 Nov 01; 26(11):1604-11. PubMed ID: 22011296
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 20. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ.
    Eur J Cancer; 2013 Mar 10; 49(4):826-34. PubMed ID: 22995582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.